Neural Regeneration Research ›› 2023, Vol. 18 ›› Issue (7): 1495-1496.doi: 10.4103/1673-5374.360319

Previous Articles     Next Articles

Pemafibrate, a potent selective peroxisome proliferator-activated receptor α modulator, a promising novel treatment for ischemic retinopathy?

Deokho Lee, Yohei Tomita, Kazuno Negishi, Toshihide Kurihara*#br#   

  1. Department of Ophthalmology, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Japan
  • Online:2023-07-15 Published:2023-01-11
  • Contact: Toshihide Kurihara, MD, PhD, kurihara@28keio.jp.
  • Supported by:
    This work was supported by the KAKENHI, Nos. 15K10881 and 18K09424 (to TK) and JST SPRING, No. JPMJSP2123 (to DL).

Abstract: Ischemic retinopathy is a retinal disease caused by ischemic attacks. Ischemia is a common pathologic mechanism in various retinal disorders and diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma, or vascular occlusion (Osborne et al., 2004). Although various murine models have been developed to understand a series of metabolic mechanisms induced by retinal ischemia and further used to test promising therapeutics, effective treatment in ischemic retinopathy has not been clearly suggested. This is associated with the notion that the contributing pathologic metabolic pathways might be enormously complex.